Table 3.
Authors | Complications | Cases (%) | Controls (%) | Risks of complications, OR (95% CI) |
Marchal[22] | Early Minor (10 d) | 15 | 13 | 1.2 (0.3-4.3) |
Late Minor (3 mo) | 2.50 | 5.10 | 1.1 (0.3-4.0) | |
Early Major (10 d) | 12.50 | 7.70 | 1.7 (0.3-7.7) | |
Late Major (3 mo) | 17.50 | 12.80 | 1.4 (0.4-5.0) | |
Colombel[23] | Septic | 17 | 0.9 (0.4-1.9) | |
Non-septic | 23 | 1.0 (0.5-2.0) | ||
Appau[24] | 30 d readmission | 20 | 9.4 + 2.9 | 2.3 (1.0-5.3) |
30 d sepsis | 20 | 9.7 + 5.8 | 2.6 (1.1-6.1) | |
30 d intra-abdominal abscess | 10 | 4.3 + 4.3 (Non IFX + pre IFX group) | 5.8 (1.7-19.7) | |
Kunitake[29] (combined study) | Post-operative cumulative complications | 16.80 | 15.70 | 1.1 (0.6-2.0) |
IFX: Infliximab; OR: Odd ratio; CI: Confidence interval.